We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
More drug firms can expect to go belly up unless they adopt a new approach to developing products that includes using statistical measures to identify successful drug candidates early and contributing clinical information to build drug and disease models that can be shared industrywide, an expert says.
Pharmaceutical patents play only a minimal role in the delivery of needed drugs to African countries, according to experts at a conference that focused on other access barriers such as poor infrastructure and high tariffs.
The FDA rejection of Barr Pharmaceutical’s bid for OTC status for its controversial Plan B emergency oral contraceptive was based on scientific analysis of the data, and not political pressure, according to a top FDA official who pointed to a possible future approval.
The rest of the year should be good for generic drugmakers, says a pharmaceutical analyst who also warns that next year could be tougher on firms’ bottom lines.
Mylan Laboratories on May 11 reported that net revenues decreased 6 percent to $333.4 million in the first three months of 2004, which is the fourth quarter of the fiscal year.
Andrx announced May 12 that it had entered into an agreement with Genpharm to obtain the firm’s exclusive U.S. marketing rights for a generic version of GlaxoSmithKline’s (GSK’s) antidepressant Paxil (paroxetine) in the 10-, 20-, 30- and 40-mg strength tablets.
Ivax has shipped the first generic version of Bristol-Myers Squibb’s (BMS’) Type 2 diabetes drug Glucovance (glyburide/metformin HCl) tablets, a move that triggered the launch of BMS’ authorized generic product distributed by Par Pharmaceutical.
Generic firms are expected to post strong growth for the rest of the year, says a pharmaceutical analyst who also warns that next year could be tougher on firms’ bottom lines.
Pfizer has agreed to plead guilty to federal criminal charges, enter into a corporate integrity agreement (CIA) with the HHS Office of Inspector General and pay $430 million to settle allegations that its Warner-Lambert unit caused doctors to submit Medicaid claims for unapproved uses of one of its drugs.